Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Cell - 14 Jun 2018

Wu Yi-Mi, Cieślik Marcin, Lonigro Robert J, Vats Pankaj, Reimers Melissa A, Cao Xuhong, Ning Yu, Wang Lisha, Kunju Lakshmi P, de Sarkar Navonil, Heath Elisabeth I, Chou Jonathan, Feng Felix Y, Nelson Peter S, de Bono Johann S, Zou Weiping, Montgomery Bruce, Alva Ajjai, Robinson Dan R, Chinnaiyan Arul M

Abstract excerpt

Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer (mCRPC) samples, we identified a novel subtype of prostate cancer typified by biallelic loss of CDK12 that is mutually exclusive with tumors driven by DNA repair deficiency, ETS fusions, and SPOP mutations. CDK12 loss is enriched in mCRPC relative to clinically localized disease and characterized by focal tandem duplications...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Cyclin-Dependent Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic Instability

Share to Programmed Cell Death 1 Receptor

Share to Prostate

Share to Prostatic Neoplasms

Share to RNA, Small Interfering

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 29906450
DOI: 10.1016/j.cell.2018.04.034
PMCID: PMC6084431

Genes

CDK12
SPOP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.PMID 29906450Read ↗

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator PhenotypeSemantic proximity Read ↗

Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.Semantic proximity Read ↗

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Semantic proximity Read ↗

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.Semantic proximity Read ↗

<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalitySemantic proximity Read ↗

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Characterizing CDK12-Mutated Prostate CancersSemantic proximity Read ↗

The Molecular Taxonomy of Primary Prostate Cancer.Semantic proximity Read ↗

Integrative clinical genomics of advanced prostate cancer.Semantic proximity Read ↗

Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defectsSemantic proximity Read ↗

The genomic complexity of primary human prostate cancerSemantic proximity Read ↗

Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision MakingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.